Personalized Cancer Evaluation (PERCEVAL) Method and Software
Cancer represents the leading cause of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths in 2012. This number is predicted to rise by approximately 70% over the next two decades according to the World Health Organization. Prognosis depends heavily on both early detection and frequent monitoring of the patient's response to treatment. Cancerous tumors shed nucleic acids into blood, which can be detected by ultra-deep sequencing of mitochondrial DNA (mtDNA). This method has the potential to provide early detection in asymptomatic individuals or those with vague, ...
Source: NIH OTT Licensing Opportunities - February 12, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Monoclonal Antibodies for Specific Detection of Dengue Virus Sub-type 4 in Human Serum
Dengue Virus (DENV) non-structural protein 1 (NS1) is secreted in blood during the acute phase of viremic DENV infection. While there are commercially available ELISA assays for DENV NS1 detection, these tests have limited sensitivity (50-70%), do not determine the serotype of the infecting DENV, do not detect all four serotypes equally, or are less sensitive in subsequent DENV infections. There is a critical need for serotype specific diagnostics to inform public health and potentially clinical care interventions. CDC developed three hybridoma cell lines and three DENV-4 serotype-specific monoclonal antibodies (mAbs) for ...
Source: NIH OTT Licensing Opportunities - February 12, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Zika Virus NS1 Protein Monoclonal Antibodies for Research, Development, and Novel Diagnostics
Zika virus is a flavivirus that is spread by the bite of infected Aedes mosquitoes. The current outbreak and swift dissemination/spread of Zika virus (ZIKV) and its linkage to birth defects and neurological syndromes has prompted the development of novel diagnostic tests. Because ZIKV is serologically similar to other flaviviruses such as dengue virus (DNV), cross-reactivity occurs in diagnostic tests and can result in misdiagnoses. This is especially evident in populations that live in dengue-endemic regions or have received heterologous flaviviral vaccines (i.e., yellow fever 17D). CDC researchers have developed seven mo...
Source: NIH OTT Licensing Opportunities - February 9, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Mobile Interconnected Evaluation and Learning Software
The National Institute on Drug Abuse (NIDA), Biomedical Informatics section, developed the Mobile Interconnected Evaluation& Learning (MIEL) as a mobile health application. MIEL is used for real-time communication of patient-reported assessment data associated with automatically collected geolocation data on one side and the user ’s enterprise-scale patient record system on the other. The reported data are for treating polydrug substance abuse or other modalities, as well as the associated risky behaviors, and are interconnected to the patient’s electronic health record system managed at the research facili...
Source: NIH OTT Licensing Opportunities - February 9, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Zika Virus NS1 Protein Monoclonal Antibodies for Research, Development, and Novel Diagnostics
Zika virus is a flavivirus that is spread by the bite of infected Aedes mosquitoes. The current outbreak and swift dissemination/spread of Zika virus (ZIKV) and its linkage to birth defects and neurological syndromes has prompted the development of novel diagnostic tests. Because ZIKV is serologically similar to other flaviviruses such as dengue virus (DNV), cross-reactivity occurs in diagnostic tests and can result in misdiagnoses. This is especially evident in populations that live in dengue-endemic regions or have received heterologous flaviviral vaccines (i.e., yellow fever 17D). CDC researchers have developed seven mo...
Source: NIH OTT Licensing Opportunities - February 9, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Substituted Quinoline Analogs as Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors
Aldehyde dehydrogenase enzymes (ALDHs) have a broad spectrum of biological activities through the oxidation of both endogenous and exogenous aldehydes. Unbalanced biological activity of ALDHs has been associated with a variety of disease states such as alcoholic liver disease, Parkinson ’s disease, obesity, and Cancer. Increased expression of ALDH1A1 has been identified in a wide-range of human cancer stem cells and is associated with cancer relapse and poor prognosis, raising the potential of ALDH1A1 as a therapeutic target.We performed a systematic medicinal chemistry optimization and biological characterization of...
Source: NIH OTT Licensing Opportunities - February 6, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Heartland Virus Humanized Monoclonal Antibodies for Diagnostic and Therapeutic Development
Heartland virus (HRTV) is a novel tick-borne virus first discovered in 2009 that causes flu-like symptoms such as fever, headaches, fatigue, muscle aches, and diarrhea. Patients with HRTV often have low white blood cell counts, low platelet counts, and abnormal liver function tests which can become severe. Cases of Heartland virus disease have been identified in the Midwestern and southern United States. There are no vaccines to prevent or medications to treat Heartland virus infections. HRTV presents symptoms and generates a similar immune response to other tick-borne viruses, making diagnosis difficult. In order to devel...
Source: NIH OTT Licensing Opportunities - January 30, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Heartland Virus Humanized Monoclonal Antibodies for Diagnostic and Therapeutic Development
Heartland virus (HRTV) is a novel tick-borne virus first discovered in 2009 that causes flu-like symptoms such as fever, headaches, fatigue, muscle aches, and diarrhea. Patients with HRTV often have low white blood cell counts, low platelet counts, and abnormal liver function tests which can become severe. Cases of Heartland virus disease have been identified in the Midwestern and southern United States. There are no vaccines to prevent or medications to treat Heartland virus infections. HRTV presents symptoms and generates a similar immune response to other tick-borne viruses, making diagnosis difficult. In order to devel...
Source: NIH OTT Licensing Opportunities - January 30, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Regenerative Therapy for Cartilage Damage
The subject technology discloses a tissue engineering method for treating cartilage damage. Stem cells from bone marrow are attached to a novel scaffold, hyaluronic acid-coated fibrin microbeads, and transferred to a live host to form cartilage. The regenerated cartilage is stable and not hypertrophic, which has been problematic in the current regenerative methods.IC: NIDCRNIH Ref. No.: E-152-2017/0Advantages: Coating with hyaluronic acid makes the fibrin microbeads more stable for mature cartilage formation.The new hyaline cartilage is stable and hypertrophy-resistant.Applications: A novel scaffold, hy...
Source: NIH OTT Licensing Opportunities - January 25, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D), Compatible with Advanced Fluorescence Microscopy Imaging
NIH immunologists have created a solution, Clearing-enhanced 3D (Ce3D), that can be used to make entire organs extremely transparent (top right panel). This allows the tissue to be imaged using advanced fluorescence microscopy techniques (bottom panel). Unlike current tissue clearing solutions, the Ce3D tissue clearing solution is robustly compatible with a variety of staining methods, and preserves tissue morphology and reporter fluorescence. Ce3D enabled microscopy provides unprecedented insight into the spatial organization of cells within intact organs. Further, when Ce3D enabled microscopy is coupled with multiplexed ...
Source: NIH OTT Licensing Opportunities - January 19, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D), Compatible with Advanced Fluorescence Microscopy Imaging
NIH immunologists have created a solution, Clearing-enhanced 3D (Ce3D), that can be used to make entire organs extremely transparent (top right panel). This allows the tissue to be imaged using advanced fluorescence microscopy techniques (bottom panel). Unlike current tissue clearing solutions, the Ce3D tissue clearing solution is robustly compatible with a variety of staining methods, and preserves tissue morphology and reporter fluorescence. Ce3D enabled microscopy provides unprecedented insight into the spatial organization of cells within intact organs. Further, when Ce3D enabled microscopy is coupled with multiplexed ...
Source: NIH OTT Licensing Opportunities - January 19, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines
Rotavirus is a highly contagious, diarrhea-inducing pathogen that annually causes approximately 250,000 deaths worldwide and millions of hospitalizations, especially afflicting infants and young children. One strategy to combat this virus is through vaccination. Continuing safety and efficacy concerns with the currently existing live, oral vaccines against rotavirus have led researchers to search for alternative treatment approaches, such as vaccines containing inactivated rotavirus.This technology describes a method for inactivating rotavirus. Traditional inactivation strategies use chemicals that reduce antigenicity (by ...
Source: NIH OTT Licensing Opportunities - January 16, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Portable Laser-Operated Counterfeit Drug Identifier (CoDI) for Tablets
Counterfeit drugs (also known as “fake or falsified medicines”) have become a major world-wide public health concern. Falsified medicines may contain toxic substances, the wrong active ingredients, suboptimal amounts of active ingredients, or no active ingredients at all. CDC researchers developed a portable (handheld), battery -operated, and relatively inexpensive device that non-trained personnel can use quickly to evaluate a particular branded tablet for authenticity. The low-cost and simple-to-use CoDI can aid the general public as well as hospitals, clinics, and pharmacies to assess drug quality. The CoDI ...
Source: NIH OTT Licensing Opportunities - January 16, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines
Rotavirus is a highly contagious, diarrhea-inducing pathogen that annually causes approximately 250,000 deaths worldwide and millions of hospitalizations, especially afflicting infants and young children. One strategy to combat this virus is through vaccination. Continuing safety and efficacy concerns with the currently existing live, oral vaccines against rotavirus have led researchers to search for alternative treatment approaches, such as vaccines containing inactivated rotavirus.This technology describes a method for inactivating rotavirus. Traditional inactivation strategies use chemicals that reduce antigenicity (by ...
Source: NIH OTT Licensing Opportunities - January 16, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Compositions and Methods for Blocking Transmission of Plasmodium
According to the World Health Organization, about 3.2 billion people – nearly half of the world's population – are at risk of infection by Plasmodium parasites, resulting in malaria. An estimated 214 million cases and 438,000 deaths were due to malaria in 2015.P47 protein expressed by Plasmodium species allow malaria parasites to evade the mosquito immune system, thereby facilitating the transmission of malaria parasites. NIAID inventors have discovered the region of P47 protein responsible for the immune evasion function of this protein. Specific sequences of protein fragments of P47 have proven to be both hig...
Source: NIH OTT Licensing Opportunities - January 11, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Compositions and Methods for Blocking Transmission of Plasmodium
According to the World Health Organization, about 3.2 billion people – nearly half of the world's population – are at risk of infection by Plasmodium parasites, resulting in malaria. An estimated 214 million cases and 438,000 deaths were due to malaria in 2015.P47 protein expressed by Plasmodium species allow malaria parasites to evade the mosquito immune system, thereby facilitating the transmission of malaria parasites. NIAID inventors have discovered the region of P47 protein responsible for the immune evasion function of this protein. Specific sequences of protein fragments of P47 have proven to be both hig...
Source: NIH OTT Licensing Opportunities - January 11, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

DNA Probes to Rapidly Screen Candida glabrata Isolates for Echinocandin Resistance to Antifungal Treatment
Candida glabrata is one causative agent of common fungal infections such as candidemia, or Candida (a yeast) present in the bloodstream. Vulnerable populations that can acquire candidemia include immunocompromised individuals such as the elderly and patients receiving chemotherapy. Echinocandins, which disrupt the fungal cell wall, are the most commonly prescribed antifungal treatment for Candida glabrata-induced candidemia. However, mutations in the FKS (FKS1 and FKS2) genes have been shown to cause C. glabrata to become resistant to echinocandins. Currently, resistance to echinocandins is detected by susceptibility testi...
Source: NIH OTT Licensing Opportunities - January 5, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Nanoparticles for the targeted treatment of infected cells
The National Cancer Institute seeks parties interested in collaborative research to license or co-develop and commercialize therapeutic RNA/DNA nanoparticles.IC: NCINIH Ref. No.: E-039-2012Advantages: Novel way for multiple functionality delivery and activationEnhanced chemical stability and pharmacokinetics due to the average size of nanoparticles exceeding 10nmIncreased specificity for selecting cells of interest   using more than one target geneApplications: Therapeutic siRNA for cancer and viral infections  Diagnostic to visualize cancerous or virus-infected cells or track delivery and eff...
Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma
The National Cancer Institute seeks parties to license human monoclonal antibodies and immunoconjugates and co-develop, evaluate, and/or commercialize large-scale antibody production and hepatocellular carcinoma (HCC) xenograft mouse models.IC: NCINIH Ref. No.: E-130-2011Advantages: Monoclonal antibodies create a level of specificity that can reduce deleterious side-effectsMultiple treatment strategies available including the killing of cancer cells with a toxic agent or by inhibiting cell signalingNon-invasive and potentially non-liver toxic alternative to current HCC treatment strategiesApplications: ...
Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Development of wildtype and knockout brain endothelial reporter cells
The National Cancer Institute seeks parties interested in co-development of safe and effective TEM5 agonists and/or antagonists that modulate WNT signaling.IC: NCINIH Ref. No.: E-079-2015Advantages: TEM5 is selectively upregulated in cerebrovasculature of tumorsTEM5 inhibitors have less potential for causing side effects compared to other Wnt signaling inhibitorsApplications: High throughput screen for TEM5 (GPR12) inhibitorsDevelopment Status: Discovery (Lead Identification)Updated On: Dec 20, 2017Provider Classifications: Publications: Licensing Contacts: Lead Inventor: I...
Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Monoclonal antibodies that target cancer
The NCI Cancer and Inflammation Program is seeking parties to license monoclonal antibodies against the insulin-like growth factor for the treatment of cancer.IC: NCINIH Ref. No.: E-212-2011Advantages: m610.27 and m630 are the first characterized antibodies that target non-overlapping epitopes on IGF-IIm660 was generated from two domains; one each from m610.27 and m630.Small size of the m610.27 and m630 domains prevent overlapping in binding to IGF-II.Applications: Therapeutic for the treatment of various human diseases associated with aberrant cell growth and motility such as breast, prostate, and leuk...
Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Nanoparticle delivery of lung cancer therapeutic
The National Cancer Institute seeks parties interested in licensing or co-developing an improved treatment for non-small cell lung cancer based on inhalation of nano- and microparticle therapeutics.IC: NCINIH Ref. No.: E-159-2014Advantages: Optimized particle size for intratracheal deliveryImproved efficacy, PK, and PD compared to other CpG formulationsApplications: Adjuvant or synergistic therapeutic to enhance efficacy of existing treatment regimes for NSCLCDevelopment Status: Pre-clinical (in vivo)Updated On: Dec 20, 2017Provider Classifications: Patent Application: 62/024,657Publ...
Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Natural product-based anti-cancer agents: aza-Englerin analogues
The National Cancer Institute seeks partners interested in licensing or collaborative research to co-develop a treatment for Ewing's Sarcoma, with a goal of preclinical evaluation leading to clinical testing.IC: NCINIH Ref. No.: E-090-2014Advantages: Novel compounds with  potent and selective inhibitory effect on select cancer cells Parent compounds are effective inin vivo cancer models.Demonstrated bioavailability after oral administration (mouse model)Applications: Chemotherapeutic for renal cell carcinoma, in addition to glucose dependent tumors.  Treatment of diseases or conditio...
Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Analogues of Modafinil for treating sleep and attention disorders
The National Institute on Drug Abuse ’s Medicinal Chemistry Section seeks partners interested in collaborative research to co-develop analogues of modafinil for the treatment of drug abuse and sleep and attention disorders.IC: NIDANIH Ref. No.: E-073-2013Advantages: Higher affinity for monoamine transporters (DAT, SERT, and NET) compared to modafinilAnalogues have lower effective dosesBetter bioavailability than modafinilImproved water solubility over modafinilApplications: Therapeutic agent for substance abuse (such as nicotine, cocaine, methamphetamine, opioids), for attention/cognitive disorder...
Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

In silico design of RNA nanoparticles
The National Cancer Institute seeks parties interested in licensing or collaborative research to co-develop RNA nanostructures using computational and synthetic methods.IC: NCINIH Ref. No.: E-059-2009Advantages: RNA nanoparticles potentially offer advantages compared to other conventional nanoparticles:They are compatible with biological systems and thus may be readily used for in vivo applications such as therapeutic and diagnostic.They are small and have a potential to move efficiently through biological barriers to a target tissue.They have multiple binding sites and thus can readily be conjugated with se...
Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Biomarkers for cancer patients treated with cancer vaccines
The National Cancer Institute ’s Chemical Biology Laboratory seeks parties to license or co-develop a diagnostic tool that identifies serum biomarkers of cancer targeting carbohydrate antigens.IC: NCINIH Ref. No.: E-234-2010Advantages: First diagnostic tool of its kind to monitor prognosis and efficacy of cancer vaccines.Applications: Diagnostic and prognostic test to monitor the progression and long-term survival of cancer patientsPredictive indicator of cancer patient's immune response to a cancer vaccineIndicator to monitor the efficacy of a cancer vaccineDevelopment Status: ClinicalUpdate...
Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Immunocompetent mouse model for tracking cancer progression
The National Cancer Institute seeks licensees or research collaborators to develop and commercialize transgenic mice having immunocompetent rat growth hormone-firefly Luciferase-enhanced green fluorescent protein.IC: NCINIH Ref. No.: E-173-2010Advantages: A more clinically relevant in vivo model of cancer progression for testing anti-cancer therapeuticsA novel pre-clinical immunodeficient mouse model that better tracks tumor development and progression.Applications: In vivo model for studying tumor progression and testing anti-cancer therapeutics using ffLuc or eGFP labeling for bioimagingUsed to screen...
Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Improved Pepper Spray for Repellency and Incapacitation
The National Cancer Institute seeks partners to license a composition for use in an aerosol or spray, that when administered, causes a painful stimulation and incapacitates a person for only a brief period.IC: NCINIH Ref. No.: E-048-2010Advantages: Incapacitating pepper spray with reduced toxicity and enhanced safety.May reduce potential agency liability in case of an adverse response of an individual who was sprayed (due to reduced toxicity may not be as life threatening to those suffering from asthma or have hypersensitive airways as standard pepper sprays).Mixture can be incorporated into a spray, aerosol...
Source: NIH OTT Licensing Opportunities - December 20, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Methods of Analyzing Virus-Derived Therapeutics
Researchers at the National Cancer Institute ’s Biopharmaceutical Development Program recently developed massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines and oncolytic immunotherapies, for which the NCI seeks licensees or co-development collaborations.IC: NCINIH Ref. No.: E-240-2015Advantages: Provides a cost- and time-effective means of assaying a virus-derived therapeutic, such as oncolytic viruses, for viral sequence variants, for regulatory approval;RNA virus preparation steps increase the amount of viral RNA obtained;Demonstrated superiority of massively ...
Source: NIH OTT Licensing Opportunities - December 20, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

West Nile/Zika Virus Chimeras for Inactivated Zika Vaccine and Diagnostic Assay Development
Zika virus (ZIKV) is a flavivirus primarily transmitted by infected Aedes mosquitoes. Infection with ZIKV during pregnancy can affect the fetus causing microcephaly, neurological complications, and other birth defects. Adults are also at risk of developing Guillain-Barre syndrome and other neurological disorders from ZIKV infection. In response to the 2015-2016 Zika outbreak, CDC researchers developed new Zika virus chimeras that can be used for inactivated Zika vaccine candidates and faster Zika antibody (Ab) neutralization assay testing. CDC scientists successfully engineered cDNA clones for the chimeric constructs based...
Source: NIH OTT Licensing Opportunities - December 19, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Cancer-reactive T cells from Peripheral Blood
Adoptive cell therapy (ACT) using genetically engineered T-cell receptors (TCRs) is a promising cancer treatment. These TCRs target genetic mutations unique to patients and play an important role in tumor regression. However, mutation-reactive T-cells and their TCRs can be difficult to identify and isolate from patients. Therefore, we need more efficient methods of isolating mutation-reactive T-cells for use with ACT.Researchers at the National Cancer Institute (NCI) have developed a novel method of isolating mutation-reactive T-cells from a patient ’s peripheral blood lymphocytes (PBL). The researchers found that mu...
Source: NIH OTT Licensing Opportunities - December 18, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Rapid Colorimetric Detection of Zika Virus from Serum and Urine Specimens by RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification).
The Zika virus (ZIKV) can be passed from a pregnant woman to her fetus. Resulting infection by this virus can cause early miscarriage and a pattern of severe birth defects in fetuses and infants. Therefore, a rapid diagnostic assay that can be performed throughout pregnancy in a clinical setting is vital for prenatal care of women living in areas where this virus may be transmitted.CDC has developed a RT-LAMP assay for the rapid screening of ZIKV RNA from urine and serum. As few as 10 copies of ZIKV RNA per microliter can be detected using this assay, showing that it is highly sensitive. It was also shown to be highly spec...
Source: NIH OTT Licensing Opportunities - December 18, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Derivation of Novel Murine Metastatic Pancreatic Adenocarcinoma Cell Lines to Generate Orthotopic Allograft Mouse Models Useful for Preclinical Testing
Researchers at the National Cancer Institute (NCI) have developed orthotopic allograft models for pancreatic cancer that utilize low passage primary pancreatic adenocarcinoma cells or tumor fragments implanted into the cancer-free pancreata of recipient syngeneic immunocompetent mice. Tumor development in these models is more synchronized, latency is substantially shortened, and tumors develop only in one location, as pre-determined by the choice of a site for cells/tumor fragment implantation. This technology is the firstin vivo model of metastatic pancreatic cancer utilizing an orthotopic transplantation procedure, which...
Source: NIH OTT Licensing Opportunities - December 15, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules
NIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. This antibody, which has been extensively characterized by NIH researchers, is already a widely-used research tool. It is currently the only monoclonal antibody available that is specific for DNA/RNA hybrids, making it a unique reagent. It is used in immuno-fluorescence (IF) microscopy, where it can be used to detect sites of transcriptional activity and potentially sites of viral replication. It has also been used in DNA/RNA immunoprecipitation (DRIP) experiments by a variety of researchers.Aside f...
Source: NIH OTT Licensing Opportunities - December 15, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Development of GPR124 Wildtype and Knockout Brain Endothelial Reporter Cells
The National Cancer Institute seeks parties interested in co-discovery and co-development of safe and effective TEM5 agonists and/or antagonists that modulate WNT signaling.IC: NCINIH Ref. No.: E-079-2015Advantages: TEM5 is selectively upregulated in cerebrovasculature of tumorsTEM5 inhibitors have less potential for causing side effects compared to other Wnt signaling inhibitorsApplications: High throughput screen for TEM5 (GPR12) inhibitorsDevelopment Status: Discovery (Lead Identification)Updated On: Dec 7, 2017Provider Classifications: Publications: Licensing Contacts: Lead ...
Source: NIH OTT Licensing Opportunities - December 8, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

MADCO-Accelerated Multidimensional Diffusion MRI
Although multidimensional diffusion/relaxation NMR experiments are widely used in materials sciences and engineering applications, preclinical and clinical MRI applications of these techniques were not feasible. Moreover, higher-field MRI scanners posed another obstacle to translation of this NMR method. Their specific absorption rate (SAR) limits the use of multi-echo or CPMG pulse trains, so that the large amounts of data required by these methods cannot be collectedin vivo due to exceedingly long scan times. Therefore, the primary challenges this invention overcomes are the migration of NMR methods to MRI and to vastly ...
Source: NIH OTT Licensing Opportunities - December 8, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Activation of Therapeutic Functionalities with Chimeric RNA/DNA Nanoparticles for Treatment of Cancer, Viruses and Other Diseases
A new strategy based on RNA/DNA hybrid nanoparticles, which can be generally used for triggering multiple functionalities inside diseased cells is presented. Individually, each of the hybrids is functionally inactive and functional representation can only be activated by the re-association of at least two cognate hybrids simultaneously present in the same cell. Overall, this novel approach allows (i) the triggered release of therapeutic siRNAs or miRNAs inside the diseased cells, (ii) activation of other split functionalities (e.g. FRET, different aptamers, rybozymes, split proteins) intracellularly, (iii) higher control o...
Source: NIH OTT Licensing Opportunities - December 8, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Conserved Elements Vaccine for HIV
The development of an effective HIV vaccine has been an ongoing area of research. High variability in HIV-1 virus strains, however,   represents a major challenge.  Ideally, an effective candidate vaccine would provide protection against the majority of clades of HIV.  Two major hurdles to overcome are immunodominance and sequence diversity. Researchers at the National Cancer Institute (NCI) have developed a vaccine that over comes these major hurdles by utilizing a strategy that identifies conserved regions of the virus and exploits them for use in a targeted therapy.NCI researchers used conserved elements ...
Source: NIH OTT Licensing Opportunities - December 7, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

IL7R α-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)
Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment.  The Interleukin-7 receptor- α (IL-7Rα) was identified as a major pathway driving T-cell derived ALL (T-ALL). Researchers at the National Cancer Institute (NCI) developed antibodies selectively targeting IL-7Rα. Two lead antibody candidates, designated 4A10 and 2B8, ...
Source: NIH OTT Licensing Opportunities - December 7, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

IL7R α-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)
The National Cancer Institute seeks licensing and/or co-development research collaborations for further development of antibodies that selectively target IL-7R α, a major driver of T-cell derived ALL (T-ALL) and an important therapeutic target for a range of diseases.NIH Ref. No.: E-247-2015Advantages: Selectively bind IL-7R α with high (nanomolar) affinityMediates cancer cell killing through antibody-dependent cellular cytotoxicity (ADCC)Targeted therapy with potential for fewer and less severe adverse eventsWell-established regulatory pathNumerous approved products using same approach (e.g., Rituxim...
Source: NIH OTT Licensing Opportunities - December 7, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

IL7R α Specific Antibody for Treating of Acute Lymphoblastic Leukemia (ALL)
Researchers at the National Cancer Institute (NCI) have developed antibodies that selectively target IL-7R α, a major driver of T-cell derived ALL (T-ALL) and an important therapeutic target for a range of diseases. The antibodies mediate leukemic cell killing through antibody-dependent cellular cytotoxicity (ADCC) and cause a significant reduction in T-ALL cell burden when administered in a xenograft m ouse model harboring patient derived leukemia. Researchers seek licensing and/or co-development research collaborations for further development of these antibodies.NIH Ref. No.: E-247-2015Advantages: • ...
Source: NIH OTT Licensing Opportunities - December 7, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

MADCO-Accelerated Multidimensional Diffusion MRI
The marginal distribution constrained optimization (MADCO) methodology is disclosed wherein a 2D (or higher-dimensional) spectrum is estimated from initial 1D marginal distribution data. These 1D marginal distributions are used as constraints in the reconstruction of the 2D spectra. MADCO accelerates and improves the reconstruction of multidimensional NMR relaxation/diffusion spectra, making it suitable for MRI applications on a voxel-by-voxel basis by vastly reducing the amount of data acquired and data necessary for creating MRI images.NIH Ref. No.: E-173-2016Advantages: • Disruptive technologies can posit...
Source: NIH OTT Licensing Opportunities - December 7, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Conserved Elements Vaccine for HIV
Researchers at the National Cancer Institute (NCI) have developed a DNA vaccine using conserved elements (CEs) of HIV-1 Gag, administered in a prime-boost vaccination protocol. Two of the HIV Gag CE DNA vectors have been tested in a rhesus macaque model. Priming with the Gag CE vaccine and boosting with full length Gag DNA showed increased immune responses when compared to vaccination with Gag alone. Researchers seek licensing and/or co-development research collaborations for development this DNA vaccine.NIH Ref. No.: E-132-2012Advantages: • Addresses two key hurdles faced by current HIV vaccines: sequence d...
Source: NIH OTT Licensing Opportunities - December 7, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Therpeutics for Neurodegenerative Disorders and Cancer Using Lenalidomide Analogs
Inflammatory processes associated with the over-production of tumor necrosis-alpha (TNF-alpha), a potent activator of the immune system accompany numerous neurodegenerative diseases. TNF-alpha has been validated as a drug target with the development of the inhibitors Enbrel and Remicade (fusion antibodies) as prescription medications. Both, however, are large macromolecules that require direct injection and have limited brain access. The classical drug, thalidomide is being increasingly used in the clinical management of a wide spectrum of immunologically-mediated and infectious diseases, and cancers. The NIA inventors dev...
Source: NIH OTT Licensing Opportunities - December 6, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Lenalidomide Analogs for the Treatment of Neurodegenerative Disorders and Cancer
Novel thalidomide analogs and their use as immunomodulatory agents are disclosed in this invention by scientists at the National Institute on Aging (NIA). These therapeutic compounds could reduce chronic systemic and central nervous system inflammation.NIH Ref. No.: E-045-2012Advantages: • Effective smaller molecular weight compound that can enter brain among current agents• Experimental therapeutic to reduce inflammation systematically and within the brain• More effective in reducing proinflammatory cytokines than existing agentApplications: • Treatment for blood disorders (myelodysplast...
Source: NIH OTT Licensing Opportunities - December 6, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Treatment Regimens for hetIL-15
Researchers at the National Cancer Institute (NCI) developed a treatment regimens for cancer and HIV using heterodimeric IL-15 (hetIL-15). The regimens allow access to B cell follicles, germinal centers, and tumor sites that are difficult for drug entry. A combination therapy for HIV infection is also described using hetIL-15 and a conserved element vaccine. Researchers seek licensing and/or co-development research collaborations for development and commercialization of treatment regimens for HIV infection.NIH Ref. No.: E-126-2016Advantages: • Allows lymphocytes to enter viral sanctuary sites such as germina...
Source: NIH OTT Licensing Opportunities - December 6, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Schweinfurthins and Uses Thereof
Neurofibromatosis type 1 (NF1) is a genetic disorder affecting 1 per 3000 individuals on average. Patients develop a variety of developmental benign and malignant pathologies. The most common tumors associated with NF1 are peripheral sheath tumors, including neurofibromas, optical gliomas, and malignant peripheral nerve sheath tumors.Researchers at the National Cancer Institute (NCI) developed novel analogs of the natural product schweinfurthin that inhibits growth of NF1-associated pathologies. The schweinfurthin analogs show inhibitory activity against mouse and human NF1 cancer cell lines. Glioma, diffuse B cell lymphom...
Source: NIH OTT Licensing Opportunities - December 5, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Schweinfurthins and Uses Thereof
Researchers at the National Cancer Institute (NCI) developed novel analogs of the natural product schweinfurthins to treat neurofibromatosis type 1 (NF1). The compounds demonstrate effective growth inhibition in malignant peripheral nerve sheath tumor cell lines and mouse models of astrocytomas. Researchers seek licensing and/or co-development research collaboration opportunities to further develop the schweinfurthin analogs.NIH Ref. No.: E-183-2009Advantages: • Specificity of mode of action reduces potential side effects• Novel mode of action• Inhibitory activity against mouse and human NF1 cancer...
Source: NIH OTT Licensing Opportunities - December 5, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Methods of Producing Effective T-cell Populations Using Akt Inhibitors
Adoptive cell therapy uses cancer reactive T-cells to effectively treat cancer patients. Producing many persistent T-cells is critical for successful treatments. Researchers at the NCI seek licensing and/or co-development research collaborations for a novel method of producing effective T-cell populations using Akt inhibitors.NIH Ref. No.: E-013-2016Advantages: • No other pharmacologic approach available to effectively uncouple T-cell expansion and differentiation• Produces increased number of persistent, cancer reactive T-cellApplications: • Clinically-feasible method of using small molecules...
Source: NIH OTT Licensing Opportunities - December 5, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2
Studies have shown that Tissue Inhibitor of Metalloproteinases 2 (TIMP-2) suppresses tumor growth and tumor-associated angiogenesis. Currently, the main obstacle in using TIMP-2 as a biologic therapeutic has been the inability to produce sufficient quantities of the protein for testing and development.   NCIRadiation Oncology Branch (ROB) researchers have developed a unique HEK-293F cell line that stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myocardial infarct and cerebrovascular ...
Source: NIH OTT Licensing Opportunities - December 4, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research